5 minSarepta Therapeutics (NASDAQ: SRPT) recently announced that the U.S. Food and Drug Administration (FDA) has officially accepted its Supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen), its antisense oligonucleotide exon-skipping therapies for Duchenne muscular dystrophy (DMD). The primary objective of these applications is to transition both products from their current "accelerated approval" status to "traditional, full approval."
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.
From Accelerated to Traditional Approval: Evidence from ESSENCE and Real-World Data
The sNDA submissions are supported by a comprehensive evidence package comprising:
-
Data from the confirmatory Phase 3 ESSENCE study.
-
A robust body of published Real-World Evidence (RWE).
-
Long-term safety data consistently demonstrating a favorable safety profile.
While the primary endpoint of the ESSENCE study did not reach statistical significance, multiple secondary and post-hoc analyses showed consistent trends in the treatment arms:
-
Increased dystrophin expression.
-
Slower decline in functional endpoints, such as the ability to climb four stairs.
-
No new safety signals observed during long-term follow-up (up to 144 weeks).
Furthermore, integrated real-world data suggest that Sarepta’s exon-skipping portfolio may provide multi-dimensional clinical benefits, including:
-
Delaying the need for nocturnal ventilation by approximately 7.5 years (VYONDYS 53).
-
Delaying declines in pulmonary function and the need for cough-assist devices (AMONDYS 45).
-
Delaying loss of ambulation by approximately 3–4 years.
-
Reducing the risk of cardiac dysfunction (LVEF <55%) and decreasing emergency room visits and hospitalizations.
In the context of rare diseases, particularly for DMD populations characterized by slow disease progression and high heterogeneity, these real-world insights are considered vital complementary evidence.
Sarepta: Real-World Evidence is Critical for Ultra-Rare DMD Subsets
Dr. Louise Rodino-Klapac, Sarepta’s Chief Development Officer and Executive Vice President of Gene Therapy, emphasized that every mutation amenable to exon skipping in DMD corresponds to an "ultra-rare subset" with an extremely small sample size. Given this, real-world experience is indispensable for understanding the disease trajectory and the impact of the therapy.
To date, Sarepta’s exon-skipping therapies have been administered to over 1,800 patients globally, ranging from infants to adults in their 30s, consistently demonstrating sustained muscle function and slowed disease progression. The company stated it will continue to work closely with the FDA to advance the review process.
Patient Advocate Perspective: Regulatory Flexibility Remains Essential
Pat Furlong, founder and president of Parent Project Muscular Dystrophy (PPMD), noted that the FDA's acceptance of these sNDAs reflects the agency's ongoing adaptability and flexibility in rare disease drug development, while underscoring that significant unmet needs remain in the DMD landscape. She emphasized that while scientific rigor is paramount, facilitating access to viable therapeutic pathways is critically important for the DMD community.
Exon-Skipping Therapies: Mechanism and Portfolio
Sarepta’s approved exon-skipping portfolio includes:
-
EXONDYS 51® (eteplirsen)
-
AMONDYS 45® (casimersen)
-
VYONDYS 53® (golodirsen)
All three are based on the Phosphorodiamidate Morpholino Oligomer (PMO) platform. By specifically binding to the DMD pre-mRNA, they induce "skipping" of target exons to restore the production of a shortened but functional dystrophin protein. This mechanism aims to partially restore muscle structural integrity and delay disease progression.
Safety Overview (Important Considerations)
Based on currently available data, the safety profiles are as follows:
-
AMONDYS 45: Common adverse reactions include headache, cough, vomiting, and rash. Hypersensitivity and infusion-related reactions should be monitored. Long-term safety remains under observation via real-world evidence.
-
VYONDYS 53: Key risks include hypersensitivity (including anaphylaxis), fever, and rash. Animal studies have indicated potential renal toxicity; clinical guidelines recommend regular monitoring of renal biomarkers (e.g., cystatin C, urine protein/creatinine ratio).
Note: These products remain marketed under accelerated approval, and their continued approval may be contingent upon verification of clinical benefit through confirmatory studies.
Summary
The FDA’s acceptance of the sNDAs for AMONDYS 45 and VYONDYS 53 marks a critical step in the evolution of DMD exon-skipping therapies from "accelerated" to "traditional" approval. This development highlights how the integration of clinical trial data and real-world evidence is becoming a cornerstone of regulatory assessment, providing a new evaluation framework for the long-term management of ultra-rare diseases like DMD.
